Azora Therapeutics Inc AZR

$3.85 -0.02 (-0.52%)

Valuation

Market cap
55,001,000
Revenue TTM
$0
Net income TTM
$-7,980,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
42,800
Avg volume
46,968
Day's range
$3.56 – $3.90
Shares out
14,286,000
Stochastic %K
67%
Beta
1.63
Analysts
Strong Buy
Price target
$11.00

Price

Company profile

Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative...

Show more

Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative colitis. Azora Therapeutics, Inc. was formerly known as Meya Pharmaceuticals, Inc. and changed its name to Azora Therapeutics, Inc. in March 2019. The company was incorporated in 2017 and is based in Encino, California.

Industry
Biotechnology
Sector
Healthcare
Phone
(818) 276-6726
Website
https://www.azoratherapeutics.com
Address
4267 Valley Meadow Road, Encino, United States

Latest news

No headlines yet.